BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 3545351)

  • 21. Primate vascular responses to octimibate, a non-prostanoid agonist at the prostacyclin receptor.
    Merritt JE; Brown AM; Bund S; Cooper DG; Egan JW; Hallam TJ; Heagerty AM; Hickey DM; Kaumann AJ; Keen M
    Br J Pharmacol; 1991 Jan; 102(1):260-6. PubMed ID: 2043927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epoprostenol (prostacyclin, PGI2) binding and activation of adenylate cyclase in platelets of diabetic and control subjects.
    Shepherd GL; Lewis PJ; Blair IA; de Mey C; MacDermot J
    Br J Clin Pharmacol; 1983 Jan; 15(1):77-81. PubMed ID: 6342639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The antagonism by BW A868C of PGD2 and BW245C activation of human platelet adenylate cyclase.
    Trist DG; Collins BA; Wood J; Kelly MG; Robertson AD
    Br J Pharmacol; 1989 Feb; 96(2):301-6. PubMed ID: 2466517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Octimibate inhibition of platelet aggregation: stimulation of adenylate cyclase through prostacyclin receptor activation.
    Seiler S; Brassard CL; Arnold AJ; Meanwell NA; Fleming JS; Keely SL
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1021-6. PubMed ID: 2175792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological properties of the new stable prostacyclin analogue 3-Oxa-methano-prostaglandin I.
    Yamamoto T; Satoh K; Nishimura T; Horikawa N; Mine T; Hirohashi T; Hara Y
    Arzneimittelforschung; 1994 Apr; 44(4):483-90. PubMed ID: 8011001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biochemical and pharmacological activity of arene-fused prostacyclin analogues on human platelets.
    Jakubowski JA; Utterback BG; Mais DE; Hardinger SA; Braish TF; Nevill CR; Fuchs PL
    Prostaglandins; 1994 Mar; 47(3):189-201. PubMed ID: 8016389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostacyclin effects on adenylate cyclase in platelets and vascular smooth muscle: interaction with an inhibitory receptor or partial agonism?
    Rovati GE; Giovanazzi S; Negretti A; Nicosia S
    Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():263-5. PubMed ID: 7732849
    [No Abstract]   [Full Text] [Related]  

  • 28. Specificity between the anti-aggregatory actions of prostacyclin, prostaglandin E1 and D2 on platelets.
    Whittle BJ; Hamid S; Lidbury P; Rosam AC
    Adv Exp Med Biol; 1985; 192():109-25. PubMed ID: 2871707
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of TRK-100, a stable prostacyclin analogue, on regulation of cyclic AMP metabolism in platelets.
    Nogimori K; Kajikawa N; Nishio S; Yajima M
    Prostaglandins; 1989 Feb; 37(2):205-12. PubMed ID: 2543034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conversion of prostacyclin to 6 oxo prostaglandin E1 by rat, rabbit, guinea-pig and human platelets.
    Griffiths RJ; Moore PK
    Br J Pharmacol; 1983 Oct; 80(2):395-402. PubMed ID: 6360281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet interaction with vascular smooth muscle in synthesis of prostacyclin.
    Hechtman DH; Kroll MH; Gimbrone MA; Schafer AI
    Am J Physiol; 1991 May; 260(5 Pt 2):H1544-51. PubMed ID: 1903602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction of prostaglandin D2 with prostacyclin, carbacyclin and the hydantoin prostaglandin, BW245C, in guinea-pig platelets.
    Hamid S; Whittle BJ
    Br J Pharmacol; 1985 May; 85(1):285-90. PubMed ID: 2992652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential effects of in vitro ethanol on prostaglandin E1-sensitive adenylate cyclase from smooth muscle cells and platelets.
    Noe M; Oliva D; Corsini A; Soma M; Fumagalli R; Nicosia S
    J Cyclic Nucleotide Protein Phosphor Res; 1985; 10(4):293-308. PubMed ID: 4040929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Desensitization of prostacyclin responsiveness in a neuronal hybrid cell line: selective loss of high affinity receptors.
    Leigh PJ; MacDermot J
    Br J Pharmacol; 1985 May; 85(1):237-47. PubMed ID: 2992650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostacyclin and prostaglandin E1: molecular mechanisms and therapeutic utility.
    Kerins DM; Murray R; FitzGerald GA
    Prog Hemost Thromb; 1991; 10():307-37. PubMed ID: 1848945
    [No Abstract]   [Full Text] [Related]  

  • 36. Prostacyclin.
    Weksler BB
    Prog Hemost Thromb; 1982; 6():113-38. PubMed ID: 6762610
    [No Abstract]   [Full Text] [Related]  

  • 37. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
    Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
    Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostacyclin-lipoprotein interactions. Studies on human platelet aggregation and adenylate cyclase.
    Colli S; Maderna P; Tremoli E; Baraldi A; Rovati GE; Gianfranceschi G; Nicosia S
    Biochem Pharmacol; 1985 Jul; 34(14):2451-7. PubMed ID: 3893439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A chemically stable analogue, 9 beta-methyl carbacyclin, with similar effects to epoprostenol (prostacyclin, PGI2) in man.
    O'Grady J; Hedges A; Whittle BJ; Al-Sinawi LA; Mekki QA; Burke C; Moody SG; Moti MJ; Hassan S
    Br J Clin Pharmacol; 1984 Dec; 18(6):921-33. PubMed ID: 6085004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The putative prostacyclin receptor antagonist (FCE-22176) is a full agonist on human platelets and NCB-20 cells.
    Wilkins AJ; MacDermot J
    Eur J Pharmacol; 1986 Aug; 127(1-2):117-9. PubMed ID: 2428638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.